| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.938 | 0.002 | 0.938 | Vasodilator, coronary | 0.445 0.024 DBMET02937 0.367 0.047 DBMET02938 0.3 0.087 DBMET02940 0.374 0.045 DBMET02941 | ||
| 0.915 | 0.002 | 0.915 | Calcium channel blocker | 0.681 0.003 DBMET02937 0.572 0.004 DBMET02938 0.294 0.01 DBMET02940 0.475 0.004 DBMET02941 | ||
| 0.832 | 0.001 | 0.832 | Calcium antagonist | 0.327 0.004 DBMET02937 0.259 0.007 DBMET02938 0.129 0.03 DBMET02940 0.241 0.009 DBMET02941 | ||
| 0.829 | 0.003 | 0.829 | Calcium channel (voltage-sensitive) blocker | 0.468 0.004 DBMET02937 0.384 0.005 DBMET02938 0.183 0.021 DBMET02940 0.308 0.006 DBMET02941 | ||
| 0.822 | 0.001 | 0.822 | Calcium channel L-type blocker | 0.571 0.002 DBMET02937 0.548 0.002 DBMET02938 0.3 0.004 DBMET02940 0.458 0.003 DBMET02941 | ||
| 0.714 | 0.001 | 0.714 | Calcium channel activator | 0.576 0.003 DBMET02937 0.527 0.004 DBMET02938 0.558 0.003 DBMET02940 0.514 0.004 DBMET02941 | ||
| 0.707 | 0.004 | 0.707 | Vasodilator | 0.356 0.032 DBMET02937 0.302 0.047 DBMET02938 0.257 0.065 DBMET02940 0.311 0.044 DBMET02941 | ||
| 0.677 | 0.003 | 0.739 | Calcium channel L-type activator | 0.668 0.003 DBMET02937 0.676 0.003 DBMET02938 0.739 0.002 DBMET02940 0.67 0.003 DBMET02941 | DBMET02940 | |
| 0.633 | 0.012 | 0.633 | Vasodilator, peripheral | 0.218 0.156 DBMET02937 0.391 0.058 DBMET02938 0.451 0.04 DBMET02940 0.46 0.038 DBMET02941 | ||
| 0.595 | 0.008 | 0.595 | Cardiotonic | 0.308 0.053 DBMET02937 0.24 0.09 DBMET02938 0.221 0.102 DBMET02940 0.233 0.094 DBMET02941 | ||
| 0.577 | 0.015 | 0.577 | Spasmolytic | 0.174 0.142 DBMET02937 0.176 0.14 DBMET02938 | ||
| 0.528 | 0.008 | 0.528 | Platelet aggregation inhibitor | 0.275 0.042 DBMET02937 0.289 0.039 DBMET02938 0.2 0.081 DBMET02940 0.463 0.012 DBMET02941 | ||
| 0.436 | 0.041 | 0.436 | Antithrombotic | 0.261 0.117 DBMET02937 0.239 0.135 DBMET02938 0.262 0.117 DBMET02940 0.372 0.057 DBMET02941 | ||
| 0.363 | 0.035 | 0.385 | Platelet antagonist | 0.175 0.122 DBMET02937 0.159 0.135 DBMET02938 0.385 0.03 DBMET02941 | DBMET02941 | |
| 0.394 | 0.077 | 0.394 | 15-Lipoxygenase inhibitor | 0.357 0.095 DBMET02937 0.271 0.149 DBMET02938 0.299 0.133 DBMET02941 | ||
| 0.342 | 0.068 | 0.684 | Cholesterol antagonist | 0.529 0.028 DBMET02937 0.663 0.011 DBMET02938 0.635 0.014 DBMET02940 0.684 0.009 DBMET02941 | DBMET02941 | |
| 0.279 | 0.011 | 0.279 | Alpha 2b adrenoreceptor antagonist | 0.138 0.045 DBMET02937 | ||
| 0.275 | 0.013 | 0.275 | Platelet activating factor antagonist | 0.121 0.062 DBMET02937 0.139 0.051 DBMET02938 0.09 0.088 DBMET02941 | ||
| 0.297 | 0.039 | 0.297 | Sigma receptor agonist | |||
| 0.264 | 0.007 | 0.264 | Neuropeptide Y1 antagonist | 0.258 0.008 DBMET02937 0.237 0.01 DBMET02938 0.241 0.009 DBMET02940 0.2 0.019 DBMET02941 | ||
| 0.253 | 0.01 | 0.253 | Alpha 2c adrenoreceptor antagonist | 0.144 0.035 DBMET02937 0.085 0.081 DBMET02938 0.096 0.07 DBMET02940 | ||
| 0.242 | 0.018 | 0.242 | Antiadrenergic | |||
| 0.238 | 0.018 | 0.238 | Adrenaline antagonist | |||
| 0.254 | 0.041 | 0.384 | Non-steroidal antiinflammatory agent | 0.23 0.052 DBMET02937 0.32 0.024 DBMET02938 0.258 0.04 DBMET02940 0.384 0.015 DBMET02941 | DBMET02941 | |
| 0.214 | 0.007 | 0.214 | Sphingomyelinase inhibitor | |||
| 0.299 | 0.095 | 0.389 | Transcription factor NF kappa B inhibitor | 0.305 0.091 DBMET02937 0.349 0.077 DBMET02938 0.311 0.089 DBMET02940 0.389 0.066 DBMET02941 | DBMET02941 | |
| 0.216 | 0.013 | 0.216 | Alpha 1b adrenoreceptor antagonist | |||
| 0.209 | 0.009 | 0.209 | Alpha 1d adrenoreceptor antagonist | |||
| 0.256 | 0.059 | 0.313 | Interleukin antagonist | 0.313 0.045 DBMET02937 | DBMET02937 | |
| 0.217 | 0.038 | 0.217 | Diuretic | 0.114 0.112 DBMET02940 0.153 0.075 DBMET02941 | ||
| 0.182 | 0.008 | 0.186 | Toll-Like receptor 3 antagonist | 0.186 0.008 DBMET02937 | DBMET02937 | |
| 0.189 | 0.019 | 0.189 | Ca(v)2.2 blocker | |||
| 0.169 | 0.02 | 0.169 | TRPA1 agonist | |||
| 0.189 | 0.049 | 0.189 | Phospholipase A2 inhibitor | 0.128 0.104 DBMET02938 0.124 0.111 DBMET02940 0.173 0.058 DBMET02941 | ||
| 0.154 | 0.021 | 0.154 | Alpha 2a adrenoreceptor antagonist | |||
| 0.138 | 0.007 | 0.138 | Beta adrenoreceptor antagonist | |||
| 0.207 | 0.076 | 0.207 | Psychostimulant | |||
| 0.164 | 0.034 | 0.164 | Alpha adrenoreceptor antagonist | |||
| 0.195 | 0.068 | 0.195 | P-glycoprotein inhibitor | 0.148 0.121 DBMET02938 | ||
| 0.194 | 0.069 | 0.194 | Hepatoprotectant | 0.132 0.131 DBMET02937 0.144 0.117 DBMET02940 | ||
| 0.148 | 0.03 | 0.148 | Mediator release inhibitor | 0.104 0.065 DBMET02941 | ||
| 0.124 | 0.005 | 0.124 | Mineralocorticoid receptor antagonist | |||
| 0.143 | 0.025 | 0.143 | Alpha 1a adrenoreceptor antagonist | |||
| 0.195 | 0.077 | 0.347 | Anesthetic general | 0.225 0.062 DBMET02937 0.347 0.024 DBMET02938 0.178 0.088 DBMET02940 0.205 0.072 DBMET02941 | DBMET02938 | |
| 0.141 | 0.031 | 0.141 | Alpha 1 adrenoreceptor antagonist | |||
| 0.111 | 0.005 | 0.165 | Thromboxane synthase inhibitor | 0.079 0.012 DBMET02937 0.107 0.005 DBMET02938 0.072 0.016 DBMET02940 0.165 0.004 DBMET02941 | DBMET02941 | |
| 0.119 | 0.018 | 0.119 | Adenosine A3 receptor antagonist | |||
| 0.202 | 0.11 | 0.459 | Hypoglycemic | 0.346 0.039 DBMET02937 0.406 0.027 DBMET02938 0.377 0.032 DBMET02940 0.459 0.019 DBMET02941 | DBMET02941 | |
| 0.115 | 0.025 | 0.153 | Glutamate release inhibitor | 0.153 0.009 DBMET02937 0.133 0.015 DBMET02938 0.15 0.01 DBMET02940 0.152 0.009 DBMET02941 | DBMET02937 | |
| 0.155 | 0.067 | 0.217 | GABA C receptor rho-2 antagonist | 0.208 0.025 DBMET02937 0.217 0.021 DBMET02938 0.196 0.031 DBMET02940 0.214 0.022 DBMET02941 | DBMET02938 | |
| 0.167 | 0.084 | 0.167 | Lipocortins synthesis antagonist | 0.134 0.132 DBMET02937 0.134 0.132 DBMET02941 | ||
| 0.122 | 0.042 | 0.122 | Adenylate kinase inhibitor | 0.107 0.057 DBMET02940 | ||
| 0.124 | 0.049 | 0.143 | GABA C receptor antagonist | 0.143 0.034 DBMET02937 0.101 0.077 DBMET02940 | DBMET02937 | |
| 0.082 | 0.016 | 0.082 | Potassium channel intermediate-conductance Ca-activated blocker | 0.066 0.031 DBMET02940 | ||
| 0.105 | 0.044 | 0.105 | Alpha 2 adrenoreceptor antagonist | |||
| 0.134 | 0.075 | 0.134 | Farnesoid X receptor antagonist | |||
| 0.079 | 0.022 | 0.079 | Calcium channel T-type blocker | |||
| 0.074 | 0.023 | 0.074 | Beta 1 adrenoreceptor antagonist | |||
| 0.077 | 0.028 | 0.098 | Glutamate (mGluR6) antagonist | 0.073 0.034 DBMET02937 0.082 0.022 DBMET02938 0.09 0.016 DBMET02940 0.098 0.011 DBMET02941 | DBMET02941 | |
| 0.225 | 0.178 | 0.365 | GABA C receptor rho-3 antagonist | 0.365 0.078 DBMET02937 0.325 0.1 DBMET02938 0.293 0.121 DBMET02940 0.332 0.096 DBMET02941 | DBMET02937 | |
| 0.105 | 0.061 | 0.117 | Toll-Like receptor 4 antagonist | 0.106 0.06 DBMET02937 0.117 0.046 DBMET02938 0.094 0.081 DBMET02940 0.113 0.051 DBMET02941 | DBMET02938 | |
| 0.08 | 0.036 | 0.08 | Phosphodiesterase III inhibitor | |||
| 0.114 | 0.071 | 0.114 | Calcium channel N-type blocker | |||
| 0.168 | 0.14 | 0.168 | Immunostimulant | |||
| 0.161 | 0.134 | 0.277 | Cyclic AMP phosphodiesterase inhibitor | 0.164 0.13 DBMET02938 0.277 0.052 DBMET02940 | DBMET02940 | |
| 0.054 | 0.028 | 0.054 | Phosphorylase inhibitor | |||
| 0.171 | 0.145 | 0.171 | Peptidyltransferase inhibitor | |||
| 0.074 | 0.051 | 0.074 | Potassium channel (Tandem pore domain) blocker | |||
| 0.092 | 0.069 | 0.092 | Bile acid receptor antagonist | |||
| 0.06 | 0.039 | 0.06 | Dopamine uptake inhibitor | |||
| 0.036 | 0.017 | 0.036 | Transforming growth factor beta 2 antagonist | |||
| 0.09 | 0.078 | 0.13 | GABA C receptor rho-1 antagonist | 0.13 0.032 DBMET02937 0.091 0.075 DBMET02938 0.122 0.039 DBMET02940 0.103 0.058 DBMET02941 | DBMET02937 | |
| 0.105 | 0.095 | 0.163 | Cyclooxygenase 3 inhibitor | 0.109 0.09 DBMET02937 0.154 0.045 DBMET02938 0.12 0.077 DBMET02940 0.163 0.038 DBMET02941 | DBMET02941 | |
| 0.059 | 0.051 | 0.059 | Nitric oxide donor | |||
| 0.037 | 0.034 | 0.037 | Glutamate (mGluR1a) antagonist | |||
| 0.042 | 0.041 | 0.042 | Parathyroid hormone antagonist | |||
| 0.139 | 0.143 | 0.168 | Anticonvulsant | 0.168 0.109 DBMET02937 0.143 0.138 DBMET02941 | DBMET02937 | |
| 0.037 | 0.057 | 0.071 | Thromboxane antagonist | 0.071 0.025 DBMET02941 | DBMET02941 | |
| 0.081 | 0.103 | 0.146 | Carbonic anhydrase XV inhibitor | 0.094 0.075 DBMET02937 0.146 0.032 DBMET02940 | DBMET02940 | |
| 0.032 | 0.056 | 0.056 | Thromboxane A2 antagonist | 0.056 0.032 DBMET02941 | DBMET02941 | |
| 0.132 | 0.157 | 0.141 | Catenin beta inhibitor | 0.141 0.128 DBMET02937 0.14 0.13 DBMET02938 | DBMET02937 | |
| 0.073 | 0.099 | 0.095 | Granulocyte macrophage colony stimulating factor agonist | 0.086 0.06 DBMET02937 0.092 0.048 DBMET02938 0.086 0.059 DBMET02940 0.095 0.043 DBMET02941 | DBMET02941 | |
| 0.087 | 0.119 | 0.119 | Photosensitizer | 0.119 0.058 DBMET02938 | DBMET02938 | |
| 0.041 | 0.075 | 0.052 | Nicotinic alpha3beta2 receptor antagonist | 0.052 0.04 DBMET02938 | DBMET02938 | |
| 0.076 | 0.117 | 0.275 | Anesthetic local | 0.267 0.017 DBMET02937 0.275 0.015 DBMET02938 0.125 0.063 DBMET02940 0.202 0.032 DBMET02941 | DBMET02938 | |
| 0.049 | 0.093 | 0.073 | Interferon inducer | 0.069 0.037 DBMET02937 0.073 0.031 DBMET02938 0.059 0.055 DBMET02940 | DBMET02938 | |
| 0.067 | 0.113 | 0.109 | Interleukin 5 antagonist | 0.083 0.067 DBMET02937 0.109 0.032 DBMET02938 0.095 0.048 DBMET02940 0.094 0.048 DBMET02941 | DBMET02938 | |
| 0.03 | 0.08 | 0.04 | GABA B receptor antagonist | 0.04 0.034 DBMET02937 | DBMET02937 | |
| 0.077 | 0.128 | 0.132 | Multidrug resistance-associated protein 1 inhibitor | 0.1 0.078 DBMET02937 0.132 0.037 DBMET02938 0.095 0.087 DBMET02940 0.098 0.082 DBMET02941 | DBMET02938 | |
| 0.043 | 0.101 | 0.07 | Adenine nucleotide translocase inhibitor | 0.07 0.015 DBMET02940 0.052 0.051 DBMET02941 | DBMET02940 | |
| 0.09 | 0.151 | 0.125 | Interleukin 1 antagonist | 0.116 0.095 DBMET02937 0.125 0.081 DBMET02938 | DBMET02938 | |
| 0.031 | 0.093 | 0.136 | GABA receptor antagonist | 0.136 0.01 DBMET02937 0.061 0.031 DBMET02938 0.068 0.027 DBMET02940 0.058 0.033 DBMET02941 | DBMET02937 | |
| 0.053 | 0.118 | 0.084 | Interferon agonist | 0.081 0.051 DBMET02937 0.084 0.045 DBMET02938 | DBMET02938 | |
| 0.143 | 0.217 | 0.255 | RNA-directed DNA polymerase inhibitor | 0.216 0.078 DBMET02938 0.255 0.047 DBMET02940 0.222 0.072 DBMET02941 | DBMET02940 | |
| 0.003 | 0.091 | 0.014 | Angiotensin AT1B receptor antagonist | 0.014 0.009 DBMET02940 | DBMET02940 | |
| 0.03 | 0.122 | 0.068 | Benzodiazepine inverse agonist | 0.059 0.015 DBMET02937 0.063 0.013 DBMET02938 0.068 0.01 DBMET02940 0.059 0.015 DBMET02941 | DBMET02940 | |
| 0.018 | 0.114 | 0.036 | Purinergic P2Y2 antagonist | 0.036 0.02 DBMET02938 0.036 0.02 DBMET02940 0.036 0.02 DBMET02941 | DBMET02941 | |
| 0.029 | 0.13 | 0.049 | Cytokine production stimulant | 0.049 0.031 DBMET02937 | DBMET02937 | |
| 0.043 | 0.145 | 0.097 | GABA aminotransferase inhibitor | 0.097 0.029 DBMET02940 | DBMET02940 | |
| 0.116 | 0.219 | 0.131 | Heat shock protein 70 antagonist | 0.131 0.118 DBMET02940 | DBMET02940 | |
| 0.058 | 0.163 | 0.096 | DNA directed RNA polymerase inhibitor | 0.096 0.061 DBMET02938 0.085 0.077 DBMET02940 | DBMET02938 | |
| 0.024 | 0.141 | 0.047 | Benzodiazepine antagonist | 0.047 0.032 DBMET02938 | DBMET02938 | |
| 0.152 | 0.269 | 0.209 | Apoptosis antagonist | 0.209 0.168 DBMET02941 | DBMET02941 | |
| 0.03 | 0.149 | 0.127 | Histidine decarboxylase inhibitor | 0.127 0.024 DBMET02940 | DBMET02940 | |
| 0.032 | 0.152 | 0.083 | Transcription factor AP-1 inhibitor | 0.065 0.037 DBMET02937 0.076 0.024 DBMET02938 0.083 0.02 DBMET02941 | DBMET02941 | |
| 0.023 | 0.144 | 0.084 | GABA A receptor antagonist | 0.084 0.02 DBMET02937 0.065 0.027 DBMET02938 0.068 0.026 DBMET02940 0.059 0.031 DBMET02941 | DBMET02937 | |
| 0.011 | 0.137 | 0.054 | Farnesoid X receptor agonist | 0.054 0.013 DBMET02940 | DBMET02940 | |
| 0.004 | 0.132 | 0.064 | Prostacyclin agonist | 0.064 0.004 DBMET02941 | DBMET02941 | |
| 0.015 | 0.143 | 0.06 | Angiotensin AT1 receptor antagonist | 0.048 0.02 DBMET02938 0.06 0.006 DBMET02940 0.053 0.014 DBMET02941 | DBMET02940 | |
| 0.012 | 0.144 | 0.084 | Purinergic P2Y antagonist | 0.039 0.038 DBMET02937 0.084 0.012 DBMET02938 0.041 0.036 DBMET02940 0.084 0.012 DBMET02941 | DBMET02941 | |
| 0.053 | 0.185 | 0.212 | GABA receptor agonist | 0.165 0.029 DBMET02937 0.212 0.015 DBMET02938 0.124 0.053 DBMET02941 | DBMET02938 | |
| 0.004 | 0.14 | 0.021 | Angiotensin AT1A receptor antagonist | 0.021 0.016 DBMET02940 | DBMET02940 | |
| 0.027 | 0.164 | 0.088 | Benzodiazepine agonist | 0.076 0.043 DBMET02937 0.088 0.033 DBMET02938 0.087 0.034 DBMET02940 | DBMET02938 | |
| 0.014 | 0.157 | 0.051 | Angiotensin II receptor antagonist | 0.034 0.023 DBMET02938 0.051 0.006 DBMET02940 0.039 0.016 DBMET02941 | DBMET02940 | |
| 0.119 | 0.264 | 0.199 | 12-Lipoxygenase inhibitor | 0.199 0.153 DBMET02937 0.194 0.158 DBMET02938 0.193 0.16 DBMET02940 0.18 0.173 DBMET02941 | DBMET02937 | |
| 0.01 | 0.158 | 0.037 | Nicotinic acid receptor 2 agonist | 0.037 0.024 DBMET02940 | DBMET02940 | |
| 0.02 | 0.169 | 0.079 | Diacylglycerol O-acyltransferase inhibitor | 0.079 0.014 DBMET02938 0.045 0.043 DBMET02940 0.079 0.014 DBMET02941 | DBMET02941 | |
| 0.06 | 0.215 | 0.123 | Cytidine deaminase inhibitor | 0.123 0.098 DBMET02940 | DBMET02940 | |
| 0.089 | 0.244 | 0.195 | Interferon gamma antagonist | 0.195 0.043 DBMET02940 | DBMET02940 | |
| 0.017 | 0.174 | 0.054 | Dihydroorotase inhibitor | 0.054 0.021 DBMET02940 | DBMET02940 | |
| 0.108 | 0.268 | 0.333 | Lipoxygenase inhibitor | 0.189 0.152 DBMET02937 0.235 0.111 DBMET02938 0.333 0.056 DBMET02941 | DBMET02941 | |
| 0.077 | 0.246 | 0.219 | Insulin sensitizer | 0.149 0.135 DBMET02937 0.147 0.138 DBMET02938 0.219 0.056 DBMET02941 | DBMET02941 | |
| 0.072 | 0.244 | 0.152 | Amyloid beta precursor protein antagonist | 0.147 0.105 DBMET02938 0.152 0.1 DBMET02941 | DBMET02941 | |
| 0.009 | 0.188 | 0.034 | Nicotinic acid receptor agonist | 0.034 0.028 DBMET02940 | DBMET02940 | |
| 0.126 | 0.312 | 0.267 | Antiobesity | 0.267 0.142 DBMET02940 0.236 0.17 DBMET02941 | DBMET02940 | |
| 0.014 | 0.201 | 0.04 | Retinoic acid alpha receptor agonist | 0.04 0.025 DBMET02940 | DBMET02940 | |
| 0.088 | 0.279 | 0.224 | Succinate dehydrogenase inhibitor | 0.16 0.096 DBMET02938 0.182 0.066 DBMET02940 0.224 0.033 DBMET02941 | DBMET02941 | |
| 0.066 | 0.259 | 0.175 | Arachidonic acid antagonist | 0.134 0.108 DBMET02940 0.175 0.059 DBMET02941 | DBMET02941 | |
| 0.013 | 0.226 | 0.041 | Sphingosine 1-phosphate receptor agonist | 0.041 0.036 DBMET02941 | DBMET02941 | |
| 0.008 | 0.227 | 0.087 | Peroxisome proliferator-activated receptor alpha agonist | 0.087 0.015 DBMET02941 | DBMET02941 | |
| 0.101 | 0.322 | 0.327 | Hypoxia-inducible factor 1 alpha inhibitor | 0.327 0.054 DBMET02940 0.242 0.108 DBMET02941 | DBMET02940 | |
| 0.063 | 0.285 | 0.109 | Sphingosine 1-phosphate receptor 4 antagonist | 0.109 0.095 DBMET02940 | DBMET02940 | |
| 0.007 | 0.23 | 0.058 | Prostaglandin D2 agonist | 0.058 0.005 DBMET02941 | DBMET02941 | |
| 0.004 | 0.229 | 0.014 | Dipeptidyl peptidase IX inhibitor | 0.014 0.013 DBMET02940 | DBMET02940 | |
| 0.159 | 0.386 | 0.386 | 5 Hydroxytryptamine release inhibitor | 0.348 0.117 DBMET02938 0.386 0.087 DBMET02940 0.277 0.192 DBMET02941 | DBMET02940 | |
| 0.013 | 0.242 | 0.122 | Dihydroorotate dehydrogenase inhibitor | 0.056 0.032 DBMET02938 0.122 0.007 DBMET02940 | DBMET02940 | |
| 0.02 | 0.252 | 0.081 | CDC25B inhibitor | 0.081 0.027 DBMET02941 | DBMET02941 | |
| 0.12 | 0.359 | 0.38 | Histamine release inhibitor | 0.38 0.086 DBMET02938 0.348 0.101 DBMET02940 0.218 0.182 DBMET02941 | DBMET02938 | |
| 0.065 | 0.306 | 0.305 | Platelet adhesion inhibitor | 0.142 0.115 DBMET02937 0.197 0.073 DBMET02938 0.305 0.032 DBMET02941 | DBMET02941 | |
| 0.032 | 0.277 | 0.118 | GABA A receptor agonist | 0.078 0.067 DBMET02937 0.118 0.025 DBMET02938 | DBMET02938 | |
| 0.048 | 0.3 | 0.128 | NADPH oxidase inhibitor | 0.128 0.074 DBMET02940 | DBMET02940 | |
| 0.061 | 0.313 | 0.161 | Interleukin agonist | 0.161 0.157 DBMET02940 | DBMET02940 | |
| 0.1 | 0.353 | 0.139 | Ca2+-transporting ATPase inhibitor | 0.139 0.078 DBMET02940 | DBMET02940 | |
| 0.078 | 0.331 | 0.165 | DNA damaging | 0.165 0.152 DBMET02937 | DBMET02937 | |
| 0.129 | 0.383 | 0.205 | 5 Hydroxytryptamine uptake stimulant | 0.205 0.141 DBMET02940 | DBMET02940 | |
| 0.041 | 0.296 | 0.066 | MDM2 inhibitor | 0.066 0.05 DBMET02940 | DBMET02940 | |
| 0.068 | 0.331 | 0.113 | Sphingosine 1-phosphate receptor 2 agonist | 0.104 0.09 DBMET02937 0.113 0.069 DBMET02938 0.102 0.097 DBMET02941 | DBMET02938 | |
| 0.054 | 0.319 | 0.175 | Mannose-6-phosphate isomerase inhibitor | 0.12 0.101 DBMET02938 0.175 0.046 DBMET02940 0.119 0.103 DBMET02941 | DBMET02940 | |
| 0.031 | 0.297 | 0.069 | Bcl-xL inhibitor | 0.069 0.021 DBMET02940 | DBMET02940 | |
| 0.107 | 0.381 | 0.269 | Antibacterial | 0.269 0.16 DBMET02940 | DBMET02940 | |
| 0.015 | 0.306 | 0.067 | Sphingosine 1-phosphate receptor 4 agonist | 0.067 0.048 DBMET02940 | DBMET02940 | |
| 0.004 | 0.298 | 0.047 | Glutamate (mGluR2) antagonist | 0.047 0.009 DBMET02940 | DBMET02940 | |
| 0.011 | 0.307 | 0.08 | Prostaglandin-E synthase inhibitor | 0.08 0.039 DBMET02940 0.062 0.06 DBMET02941 | DBMET02940 | |
| 0.015 | 0.316 | 0.108 | Leukotriene synthesis inhibitor | 0.067 0.047 DBMET02940 0.108 0.022 DBMET02941 | DBMET02941 | |
| 0.079 | 0.383 | 0.272 | DNA directed DNA polymerase inhibitor | 0.272 0.178 DBMET02938 | DBMET02938 | |
| 0.03 | 0.336 | 0.073 | Cell adhesion molecule inhibitor | 0.073 0.064 DBMET02941 | DBMET02941 | |
| 0.024 | 0.332 | 0.156 | Glutamate receptor antagonist | 0.156 0.047 DBMET02940 0.104 0.092 DBMET02941 | DBMET02940 | |
| 0.016 | 0.33 | 0.123 | Protein-tyrosine phosphatase 1B inhibitor | 0.123 0.061 DBMET02941 | DBMET02941 | |
| 0.005 | 0.32 | 0.032 | HMG CoA reductase inhibitor | 0.032 0.029 DBMET02941 | DBMET02941 | |
| 0.082 | 0.404 | 0.158 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.158 0.132 DBMET02940 | DBMET02940 | |
| 0.004 | 0.326 | 0.065 | Glutamate (mGluR group II) antagonist | 0.065 0.009 DBMET02940 | DBMET02940 | |
| 0.024 | 0.346 | 0.172 | Cholesterol synthesis inhibitor | 0.126 0.06 DBMET02938 0.172 0.035 DBMET02940 0.125 0.061 DBMET02941 | DBMET02940 | |
| 0.015 | 0.34 | 0.039 | 3-Hydroxyanthranilate 3,4-dioxygenase inhibitor | 0.039 0.036 DBMET02940 | DBMET02940 | |
| 0.009 | 0.339 | 0.09 | Peroxisome proliferator-activated receptor gamma agonist | 0.09 0.034 DBMET02941 | DBMET02941 | |
| 0.019 | 0.35 | 0.085 | Glutamate (mGluR) antagonist | 0.085 0.045 DBMET02940 | DBMET02940 | |
| 0.039 | 0.371 | 0.123 | DOPA decarboxylase inhibitor | 0.123 0.042 DBMET02940 | DBMET02940 | |
| 0.032 | 0.367 | 0.113 | UDP-N-acetylglucosamine 1-carboxyvinyltransferase inhibitor | 0.113 0.044 DBMET02940 | DBMET02940 | |
| 0.007 | 0.343 | 0.041 | Leukocyte elastase inhibitor | 0.041 0.032 DBMET02941 | DBMET02941 | |
| 0.061 | 0.398 | 0.256 | Thyroid hormone antagonist | 0.182 0.178 DBMET02938 0.256 0.12 DBMET02941 | DBMET02941 | |
| 0.043 | 0.382 | 0.333 | Hypolipemic | 0.154 0.133 DBMET02937 0.276 0.057 DBMET02938 0.239 0.072 DBMET02940 0.333 0.04 DBMET02941 | DBMET02941 | |
| 0.004 | 0.346 | 0.026 | Kynurenine 3 monooxygenase inhibitor | 0.026 0.019 DBMET02940 | DBMET02940 | |
| 0.028 | 0.376 | 0.185 | Protein-tyrosine phosphatase inhibitor | 0.166 0.065 DBMET02940 0.185 0.053 DBMET02941 | DBMET02941 | |
| 0.059 | 0.407 | 0.243 | Thyroid hormone beta antagonist | 0.18 0.173 DBMET02938 0.243 0.123 DBMET02941 | DBMET02941 | |
| 0.03 | 0.382 | 0.137 | Mcl-1 antagonist | 0.137 0.104 DBMET02940 | DBMET02940 | |
| 0.037 | 0.396 | 0.106 | Cell adhesion inhibitor | 0.106 0.079 DBMET02941 | DBMET02941 | |
| 0.008 | 0.369 | 0.032 | Purinergic P2X3 antagonist | 0.032 0.028 DBMET02938 | DBMET02938 | |
| 0.042 | 0.425 | 0.107 | Interleukin 4 antagonist | 0.107 0.106 DBMET02940 | DBMET02940 | |
| 0.015 | 0.401 | 0.124 | 5-Lipoxygenase inhibitor | 0.095 0.068 DBMET02938 0.124 0.048 DBMET02941 | DBMET02941 | |
| 0.026 | 0.413 | 0.165 | Aryl hydrocarbon receptor agonist | 0.165 0.124 DBMET02940 0.158 0.129 DBMET02941 | DBMET02940 | |
| 0.03 | 0.424 | 0.108 | NADH dehydrogenase inhibitor | 0.108 0.036 DBMET02940 | DBMET02940 | |
| 0.003 | 0.397 | 0.03 | Retinoid X receptor agonist | 0.03 0.029 DBMET02940 | DBMET02940 | |
| 0.005 | 0.403 | 0.046 | Retinoid X alpha receptor agonist | 0.046 0.016 DBMET02940 | DBMET02940 | |
| 0.022 | 0.423 | 0.088 | UDP-glucose 4-epimerase inhibitor | 0.088 0.076 DBMET02940 | DBMET02940 | |
| 0.092 | 0.497 | 0.576 | Cyclophilin D inhibitor | 0.329 0.139 DBMET02937 0.441 0.071 DBMET02938 0.513 0.046 DBMET02940 0.576 0.032 DBMET02941 | DBMET02941 | |
| 0.003 | 0.409 | 0.035 | Peroxisome proliferator-activated receptor delta agonist | 0.035 0.022 DBMET02941 | DBMET02941 | |
| 0.01 | 0.427 | 0.066 | Porphobilinogen synthase inhibitor | 0.066 0.06 DBMET02940 | DBMET02940 | |
| 0.022 | 0.444 | 0.113 | Alkaline phosphatase inhibitor | 0.113 0.096 DBMET02940 | DBMET02940 | |
| 0.003 | 0.428 | 0.019 | Prostaglandin EP1 antagonist | 0.019 0.014 DBMET02940 | DBMET02940 | |
| 0.005 | 0.432 | 0.067 | Prostaglandin E2 antagonist | 0.067 0.025 DBMET02940 | DBMET02940 | |
| 0.026 | 0.453 | 0.084 | Xanthine oxidase inhibitor | 0.084 0.082 DBMET02940 | DBMET02940 | |
| 0.052 | 0.484 | 0.2 | Immunosuppressant | 0.2 0.197 DBMET02938 | DBMET02938 | |
| 0.027 | 0.461 | 0.167 | Dual specificity phosphatase 3 inhibitor | 0.167 0.082 DBMET02940 0.134 0.111 DBMET02941 | DBMET02940 | |
| 0.018 | 0.454 | 0.103 | Cystathionine beta-synthase inhibitor | 0.103 0.073 DBMET02940 | DBMET02940 | |
| 0.003 | 0.453 | 0.024 | Free fatty acid receptor 1 agonist | 0.024 0.008 DBMET02941 | DBMET02941 | |
| 0.068 | 0.521 | 0.24 | Sodium/bile acid cotransporter inhibitor | 0.24 0.139 DBMET02940 0.213 0.171 DBMET02941 | DBMET02940 | |
| 0.008 | 0.476 | 0.068 | Purinergic P2 antagonist | 0.068 0.041 DBMET02938 | DBMET02938 | |
| 0.014 | 0.482 | 0.067 | Peroxisome proliferator-activated receptor gamma antagonist | 0.067 0.06 DBMET02941 | DBMET02941 | |
| 0.078 | 0.569 | 0.123 | CC chemokine 6 receptor antagonist | 0.123 0.1 DBMET02940 | DBMET02940 | |
| 0.032 | 0.523 | 0.217 | Insulin secretagoues | 0.188 0.043 DBMET02938 0.157 0.067 DBMET02940 0.217 0.028 DBMET02941 | DBMET02941 | |
| 0.023 | 0.529 | 0.135 | Dual specificity phosphatase inhibitor | 0.135 0.112 DBMET02940 | DBMET02940 | |
| 0.03 | 0.542 | 0.196 | DNA synthesis inhibitor | 0.196 0.129 DBMET02940 | DBMET02940 | |
| 0.005 | 0.528 | 0.066 | Leukotriene antagonist | 0.066 0.044 DBMET02941 | DBMET02941 | |
| 0.005 | 0.529 | 0.113 | Prostaglandin antagonist | 0.051 0.039 DBMET02940 0.113 0.015 DBMET02941 | DBMET02941 | |
| 0.079 | 0.606 | 0.261 | Caspase 9 stimulant | 0.261 0.239 DBMET02940 | DBMET02940 | |
| 0.003 | 0.545 | 0.036 | Prostaglandin D2 antagonist | 0.036 0.009 DBMET02941 | DBMET02941 | |
| 0.018 | 0.562 | 0.139 | Alpha-N-acetylglucosaminidase inhibitor | 0.139 0.062 DBMET02940 | DBMET02940 | |
| 0.014 | 0.576 | 0.08 | Purinergic P2X1 antagonist | 0.08 0.025 DBMET02940 | DBMET02940 | |
| 0.037 | 0.662 | 0.201 | Immunomodulator | 0.192 0.174 DBMET02937 0.201 0.163 DBMET02938 | DBMET02938 | |
| 0.006 | 0.659 | 0.072 | HIV-1 integrase inhibitor | 0.071 0.047 DBMET02940 0.072 0.046 DBMET02941 | DBMET02941 | |
| 0.009 | 0.715 | 0.086 | Uric acid excretion stimulant | 0.086 0.071 DBMET02940 | DBMET02940 | |
| 0.008 | 0.81 | 0.058 | Autotaxin inhibitor | 0.058 0.03 DBMET02940 | DBMET02940 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |